Omeros Stock News

The stock price of Omeros Corporation (NASDAQ: OMER) increased by over 7% during intraday trading. This is why it happened.

Omeros Corporation (NASDAQ: OMER) has agreed to sell Omidria to Rayner Surgical Group Limited for an upfront payment of $125 million with an additional $200 million in commercial milestones. Omidr

Hohimer Wealth Management LLC raised its stake in Omeros Co. (NASDAQ:OMER) by 5.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 41,580 shares of the biopharmaceutical companys stock after buying an additional 2,000 shares during the quarter. Hohimer Wealth Management LLC owned []

Omeros Corporation (NASDAQ:OMER)s traded shares stood at 0.53 million during the last session, with the companys beta value hitting 0.70. At the close of trading, the stocks price was $7.88, to imply an increase of 1.55% or $0.12 in intraday trading. The OMER shares 52-week high remains $23.85, putting it -202.66% down since that peak Omeros Corporation (NASDAQ: OMER): Can A Stock Be Down -44.84% YTD, And Still Be A Loser Read More »

Cubist Systematic Strategies LLC boosted its holdings in Omeros Co. (NASDAQ:OMER) by 57.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 53,774 shares of the biopharmaceutical companys stock after purchasing an additional 19,687 shares during the period. Cubist Systematic Strategies LLC owned []

Dublin, Nov. 15, 2021 (GLOBE NEWSWIRE) -- The "Complement 3 Glomerulopathy (C3G) - Market Insights, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com''s offering.

Omeros Corporation (OMER) CEO Greg Demopulos on Q3 2021 Results - Earnings Call Transcript

Omeros (NASDAQ:OMER) reported its Q3 earnings results on Tuesday, November 9, 2021 at 04:00 PM. Here's what investors need to know about the announcement.

Omeros Corporation (NASDAQ: OMER) announced long-term follow-up (35 months) results from the Phase 2 trial of its MASP-2 inhibitor narsoplimab in patients with IgA nephropathy.  Treatment with nar

The average of price targets set by Wall Street analysts indicates a potential upside of 192% in Omeros (OMER). While the effectiveness of this highly sought-after metric is questionable, the positive

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its third quarter financial results for the period ended September 30, 2021, on Tuesday, Novembe

Each for reasons of their own, Atea Pharmaceuticals, Omeros, and Novavax have had a very tough time this year.

The FDA issued a Complete Response Letter (CRL) related to Omeros Corporation's (NASDAQ: OMER) marketing application for narsoplimab for hematopoietic stem cell transplant-associated thrombotic mi

Bad news the company received today from the FDA surprised investors more than it probably should have.